Amgen and Novartis have added an amendment to a licensing and collaboration agreement for the migraine

BeiGene reports findings from phase 3 trial of tislelizumab in gastric cancer (updated)

The amendments results in Novartis having sole rights to commercialize Aimovig outside of the United States and Japan. Also, Amgen no longer has to pay royalties to Novartis on sales of Aimovig in the U.S.

Also, the two companies will no longer share the commercialization costs of Aimovig in the U.S., though they will share development expenses worldwide